General Information:

Id: 2,868
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mus musculus
article
Reference: Foretz M et al.(2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120: 2355-2369 [PMID: 20577053]

Interaction Information:

Comment Metformin suppresses hepatic glucose production in the absence of AMPK catalytic subunits and in the absence of LKB1.
Formal Description
Interaction-ID: 26442

drug/chemical compound

Metformin

decreases_activity of

process

gluconeogenesis

in liver; independent of AMPK catalytic chains and independent of STK11 (LKB1)
Drugbank entries Show/Hide entries for Metformin
Comment Metformin lowers blood glucose levels in liver AMPK-deficient mice.
Formal Description
Interaction-ID: 26448

drug/chemical compound

Metformin

decreases_activity of

phenotype

hyperglycemia

independent of liver AMPK
Drugbank entries Show/Hide entries for Metformin
Comment Metformin suppresses hepatic glucose production without affecting the expression of the gluconeogenic genes PEPCK and G6Pase.
Formal Description
Interaction-ID: 26449

drug/chemical compound

Metformin

NOT affects_expression of

gene/protein

PCK1

Drugbank entries Show/Hide entries for Metformin or PCK1
Comment Metformin suppresses hepatic glucose production without affecting the expression of the gluconeogenic genes PEPCK and G6Pase.
Formal Description
Interaction-ID: 26451

drug/chemical compound

Metformin

NOT affects_expression of

gene/protein

G6PC

Drugbank entries Show/Hide entries for Metformin